Related Experiment Video
Updated: Jun 20, 2026
09:57
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
8.7K
IL-10 Modulation Increases Pyrazinamide's Antimycobacterial Efficacy against Mycobacterium tuberculosis Infection in
Varun Dwivedi1, Shalini Gautam2, Gillian Beamer2
1Disease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX.
Immunohorizons
|June 6, 2023
Summary
Short-term blockade of IL-10R1 enhances pyrazinamide efficacy, accelerating tuberculosis clearance in mice. This combination therapy shows promise for reducing overall tuberculosis treatment duration.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Tuberculosis (TB) treatment duration is a key challenge.
- Host-directed therapies (HDTs) aim to boost the immune system against Mycobacterium tuberculosis.
- Pyrazinamide, a first-line TB drug, also modulates immune function.
Purpose of the Study:
- To evaluate anti-IL-10R1 as an HDT combined with pyrazinamide.
- To determine if this combination accelerates Mycobacterium tuberculosis clearance.
Main Methods:
- Mice were treated with pyrazinamide and short-term anti-IL-10R1 blockade.
- Treated mice were assessed for Mycobacterium tuberculosis clearance.
- Comparison of pyrazinamide treatment in IL-10 deficient environment.
Main Results:
- Short-term anti-IL-10R1 blockade enhanced pyrazinamide's antimycobacterial efficacy.
- Faster clearance of Mycobacterium tuberculosis was observed in mice receiving the combination therapy.
- Pyrazinamide treatment in an IL-10 deficient environment led to sterilizing clearance.
Conclusions:
- Short-term IL-10 blockade combined with pyrazinamide accelerates TB clearance in mice.
- This approach has the potential to reduce tuberculosis treatment duration.
- Targeting IL-10 signaling offers a promising strategy for improving TB treatment outcomes.
